Download
Brochure

Twitter

Travel Info

New York Marriott Marquis



1535 Broadway
New York, New York 10036

More Information >>

Share |

Tuesday, October 16, 2012

10:45 AM - 11:30 AM
Track: Data Governance Track: Sponsored by IBM View Track

CASE STUDY: MDM STRATEGIES TO DRIVE DATA GOVERNANCE

Patrick Genyn, Senior Director Drug Development Information Governance, JANSSEN RESEARCH & DEVELOPMENT LLC
Erica Gooch, Drug Development Information Governance Lead, JANSSEN RESEARCH & DEVELOPMENT LLC

Janssen R&D is a worldwide leader in delivering innovative medicines for the treatment of an array of health concerns, including attention deficit hyperactivity disorder (ADHD), general medicine, mental health, neurologics, pain management, and women’s health. In order to produce such medicines and achieve the ultimate goal of helping people live healthy lives, effective management of information assets must be in place. The efficient mobility of data across functions and throughout the lifecycle of a drug is critical to speed decision making, increase regulatory compliance, aid interoperability between systems, facilitate reporting across databases, and decrease complexity in data aggregation. The translation of principles used in a typical MDM setting such as managing CUSTOMER or PRODUCT master data in a clinical R&D setting required a unique and customized Data Governance approach. This session will discuss best practices derived from experiences of Janssen R&D’s Drug Development Information Governance group, and will cover

•Establishing a governance model to determine overall MDM strategies

•Determining the maintenance of the MDM policy (taxonomy, reference data, ownership, relationships)

•Sustaining Data Governance via non-intrusive data quality procedures

>> Submit a question to this session's speakers

>> Return to Agenda